Edwards Lifesciences Corp (EW)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,601,100 | 1,767,400 | 1,702,000 | 916,700 | 1,166,500 |
| Revenue | US$ in thousands | 5,997,700 | 5,362,000 | 5,219,100 | 4,382,800 | 4,333,200 |
| Pretax margin | 26.70% | 32.96% | 32.61% | 20.92% | 26.92% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $1,601,100K ÷ $5,997,700K
= 26.70%
Over the past five years, Edwards Lifesciences Corp has displayed varying levels of pretax margin, with fluctuations observed annually. The pretax margin decreased from 26.83% in 2019 to 20.90% in 2020, indicating a decline in the company's profitability before considering taxes. However, the company saw an improvement in its pretax margin in 2021, reaching 32.53%, and maintained relatively stable levels in 2022 at 32.84%.
However, in 2023, the pretax margin experienced a slight decrease to 26.61%. This suggests that the company may have encountered challenges or undertaken strategies impacting its profitability in that year. Overall, while the pretax margin has exhibited fluctuations, it is essential for Edwards Lifesciences Corp to monitor and assess the factors influencing these changes to sustain and enhance its profitability in the future.
Peer comparison
Dec 31, 2023